Comparison Between Endovascular and Bronchoscopic Tumor Marker Insertion for Real-time Stereotactic-guided Radiotherapy in Lung Cancer

Launched by CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS · Dec 21, 2020

Keywords

ClinConnect Summary

This clinical trial is studying two different methods for placing small markers, called fiducial markers, near lung tumors to help guide a type of radiation treatment known as Cyberknife therapy. The goal is to see which method—endovascular (through blood vessels) or bronchoscopic (through the lungs)—is better at ensuring the markers stay in the right place during treatment. This is important because accurate placement of these markers is essential for targeting the tumor while minimizing damage to surrounding healthy tissue.

To participate in this study, you should be between 18 and 85 years old and have lung cancer, either in its early stages or more advanced stages. If you're interested, you'll undergo a procedure to have the markers placed, and researchers will monitor how well this is done, any complications that might arise, and how long the procedures take. The trial is currently recruiting participants, and it aims to provide more clarity on how these two methods compare, which could help improve treatment options for lung cancer in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Lung cancer (primary or secondary, any histological type)
• • Early stage lung cancer: patients diagnosed with stage I for which operation is contra-indicated, for example because of cardiac or pulmonary comorbidities.
• • Locally advanced lung cancer stages II - IIIB
• • Metastatic lung cancer stage IV (palliative care)
• • 18 y ≤ age ≤ 85 y
• Exclusion Criteria:
• • age \<18y
• • incapacity of judgment
• • Absence of a signed consent form